China Pharma (CPHI) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SCYNEXIS (SCYX) has outperformed China Pharma (CPHI) over the past year, losing 32.1% versus a loss of 56.6%. Over five years, SCYX leads with a -90.5% price change compared with -99.7% for CPHI. SCYNEXIS is the larger company by market cap ($42.0 million vs $41.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | SCYX |
|---|---|---|
| Share price | $0.96 | $4.22 |
| Market cap | $41.30M | $41.99M |
| 1-day change | +12.94% | -11.72% |
| YTD return | -29.75% | -16.53% |
| 1-year return | -56.63% | -32.11% |
| 5-year return | -99.69% | -90.53% |
| EPS (TTM) | $-0.42 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $9.12 |
| 52-week low | $0.38 | $3.53 |
| Distance from 52-week high | -95.00% | -53.73% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +760.90% |
| Average volume | 5.47M | 274.80K |
| Shares outstanding | 43.02M | 9.95M |
| Employees | 215 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed CPHI by 24.5 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
CPHI vs SCYX FAQ
Which is bigger, China Pharma or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $41.99M compared with $41.30M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -56.63% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and SCYNEXIS in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.